133 related articles for article (PubMed ID: 35449318)
1. DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer.
Liang X; Zhao Y; Fang Z; Shao N; Zhai D; Zhang M; Yu L; Shi Y
Mol Biol Rep; 2022 May; 49(5):3939-3947. PubMed ID: 35449318
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DLGAP1-AS2 modulates glioma development by up-regulating YAP1 expression.
Miao W; Li N; Gu B; Yi G; Su Z; Cheng H
J Biochem; 2020 Apr; 167(4):411-418. PubMed ID: 31899508
[TBL] [Abstract][Full Text] [Related]
3. LncRNA DLGAP1-AS2 regulates miR-503/cyclin D1 to promote cell proliferation in non-small cell lung cancer.
Wang L; Tang L; Ge T; Zhu F; Liu D; Guo H; Qian P; Xu N
BMC Pulm Med; 2021 Aug; 21(1):277. PubMed ID: 34454450
[TBL] [Abstract][Full Text] [Related]
4. N
Huang T; Cao L; Feng N; Xu B; Dong Y; Wang M
Bioengineered; 2021 Dec; 12(2):10935-10944. PubMed ID: 34866525
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer.
Wang X; Cheng H; Zhao J; Li J; Chen Y; Cui K; Tian L; Zhang J; Li C; Sun S; Feng Y; Yao S; Bian Z; Huang S; Fei B; Huang Z
Mol Cancer; 2022 Nov; 21(1):210. PubMed ID: 36376892
[TBL] [Abstract][Full Text] [Related]
6. The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis.
Zheng C; Li R; Zheng S; Fang H; Xu M; Zhong L
Cancer Sci; 2023 Dec; 114(12):4747-4762. PubMed ID: 37817462
[TBL] [Abstract][Full Text] [Related]
7. METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m
Zhang Q; Zhang Y; Chen H; Sun LN; Zhang B; Yue DS; Wang CL; Zhang ZF
Cell Cycle; 2022 Dec; 21(24):2602-2614. PubMed ID: 35972892
[TBL] [Abstract][Full Text] [Related]
8. Long Non-coding RNA DLGAP1-AS1 and DLGAP1-AS2: Two Novel Oncogenes in Multiple Cancers.
Zhao F; Tan F; Tang L; Du Z; Chen X; Yang Y; Zhou G; Yuan C
Curr Med Chem; 2023; 30(25):2822-2834. PubMed ID: 36121088
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
10. The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10.
Liu Z; Pan L; Yan X; Duan X
FEBS Open Bio; 2021 Feb; 11(2):413-422. PubMed ID: 33301605
[TBL] [Abstract][Full Text] [Related]
11. DLGAP1-AS2 promotes human colorectal cancer progression through trans-activation of Myc.
Ren C; Han H; Pan J; Chang Q; Wang W; Guo X; Bian J
Mamm Genome; 2022 Dec; 33(4):672-683. PubMed ID: 36222892
[TBL] [Abstract][Full Text] [Related]
12. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.
Xue X; Yang YA; Zhang A; Fong KW; Kim J; Song B; Li S; Zhao JC; Yu J
Oncogene; 2016 May; 35(21):2746-55. PubMed ID: 26364613
[TBL] [Abstract][Full Text] [Related]
13. lncRNA DLGAP1-AS2 Knockdown Inhibits Hepatocellular Carcinoma Cell Migration and Invasion by Regulating miR-154-5p Methylation.
Chen K; Zhang Z; Yu A; Li J; Liu J; Zhang X
Biomed Res Int; 2020; 2020():6575724. PubMed ID: 33195697
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p.
Peng X; Wei F; Hu X
J Cell Biochem; 2020 Feb; 121(2):1953-1962. PubMed ID: 31633236
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DLGAP1-AS2 overexpression associates with gastric tumorigenesis: a promising diagnostic and therapeutic target.
Soltani R; Amini M; Mazaheri Moghaddam M; Jebelli A; Ahmadiyan S; Bidar N; Baradaran B; MotieGhader H; Asadi M; Mokhtarzadeh A
Mol Biol Rep; 2022 Jul; 49(7):6817-6826. PubMed ID: 34981339
[TBL] [Abstract][Full Text] [Related]
17. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
19. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DLGAP1-AS2 promotes the radioresistance of rectal cancer stem cells by upregulating CD151 expression via E2F1.
Xiao SY; Yan ZG; Zhu XD; Qiu J; Lu YC; Zeng FR
Transl Oncol; 2022 Apr; 18():101304. PubMed ID: 35144091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
